[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Graz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":678},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,45,78,107,134,163,189,213,254,291,319,341,365,396,429,448,474,495,519,540,566,585,605,631,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100628744","vessel-recoil-in-specific-clti-populations-100628744",false,"NCT07465627","Vessel Recoil in Specific CLTI Populations","Early Vessel Recoil Following Below-the-knee (BTK) Artery Treatment With the Spur Peripheral Retrievable Scaffold System in Specific Patient Populations With Chronic Limb-threatening Ischemia (CLTI) - The DEEPER CHALLENGE Single Center Prospective Study","General Inclusion Criteria:\n\n1. Subject is willing and able to provide informed consent\n2. Subject is able to comply with the study protocol and with follow-up\n3. Life expectancy \\>1 year in the investigator's opinion\n4. Subject is \\> 18 years of age\n5. Subject must have symptoms of limb ischemia, determined by clinical symptoms of RC 4 or 5, including rest pain (RC 4) and\u002For minor tissue loss (RC 5), that in the opinion of the investigator are not amenable to conservative medical therapy and require endovascular intervention for alleviation of symptoms and tissue preservation\n6. Subject has stenotic, restenotic or occlusive lesions located in BTK vessels in pre-screening with CTA, MRA or angiography prior to the index procedure.\n7. Subject suffers from diabetes and\u002For receives chronic hemodialysis for KD (for at least 6 months)\n\n   * Diabetes cohort: Subject requires for estimated glomerular filtration rate (eGFR) ≥ 25ml\u002Fmin (within 30 days of procedure)\n   * Hemodialysis cohort: Subject has been receiving hemodialysis treatment for ≥ 6 months. (Note: subjects with diabetes who also receive chronic hemodialysis will be excluded from the diabetes cohort and will be included only in the hemodialysis cohort).\n\nAngiographic Inclusion Criteria:\n\n1. Target lesion can be successfully crossed with a guidewire.\n2. Target lesion must be located in BTK arteries. Treatment of the distal popliteal segment (P3) is permitted provided that sizing remains appropriate (no more than 4.5 mm in diameter).\n3. Target vessel reconstitutes at or above the medial ankle, with the target treated segment extending no more than 10 mm beyond the ankle.\n\n   1. If the anterior tibial or posterior tibial arteries are treated, there must be inline flow to the foot.\n   2. If the peroneal artery is treated, there must be at least one collateral supplying the foot.\n4. Target vessel reference diameter is measured to be between 2.5 mm to 4.5 mm in diameter.\n5. Only one artery may be treated with the Spur device.\n\n   a. Non-target infrapopliteal lesions requiring treatment must be treated prior to treatment of the target lesion. Treatment of the target vessel\u002Flesion with the Spur device may be performed only if treatment of the non-target vessel(s)\u002Flesion(s) does not result in a complication which may compromise the outflow of the target lesion or result in a major adverse limb event.\n6. The treated segment is defined as the total length of artery treated with the Spur device. Total target treatment length must be \\\u003C 250mm with a maximum segment of 220 mm separated by 30 mm of healthy tissue between treated lesions.\n7. Successful pre-dilatation of the target lesion as outlined in the procedure instructions, defined as resulting in stenosis ≤ 50%, without resulting flow limiting (Type D or greater) dissection, thrombus, or aneurysm by angiography prior to the insertion of the Spur device.\n8. Iliac, SFA and popliteal inflow lesions can be treated during the index procedure. Inflow lesions treated intraprocedure must be treated first, prior to consideration of treatment of infrapopliteal lesions. Inflow lesions must have a healthy vessel segment of \\>30 mm between the study lesion and the treated segment, defined as ≤ 50% stenosis.\n9. The Spur must be deployed from antegrade access.\n\nGeneral Exclusion Criteria:\n\n1. Subject is unwilling or unlikely to comply with the duration of the study (up to 12 months +\u002F-30 days post intervention) in the opinion of the investigator\n2. Subject is pregnant or planning to become pregnant during the course of the trial\n3. Subject is breastfeeding or planning to breastfeed during the course of the trial\n4. Subject has an active and uncontrolled systemic infection, including septicemia or bacteremia\n5. Subject has documented active osteomyelitis proximal to the phalanges of the target limb. Osteomyelitis in the digit(s) of the target foot is permitted.\n6. Subject has a wound above the ankle and\u002For a heel wound\n7. Subject has planned or had previous major (above the ankle) amputation of the target limb. A planned or previous minor (transmetatarsal amputation or digit amputation) is permitted.\n8. Subject with poor and insufficient general condition and\u002For comorbidities not allowing for endovascular treatment as per the investigator's discretion\n9. Diabetes cohort: subject has impaired renal function as defined by an eGFR \\\u003C 25 mL\u002Fmin within 30 days of procedure\n10. Hemodialysis cohort: subject has been receiving hemodialysis treatment for less than 6 months\n11. Subject with inability to comply with antiplatelet and\u002For anticoagulation therapy as per the facility's standard of care\n12. Subject with known allergies or sensitivities to heparin, antiplatelet drugs, other anticoagulant therapies which do not allow for an adequate peri- and post-procedural treatment\n13. Subject with known allergies or sensitivities to Paclitaxel or Sirolimus balloon coatings\n14. Subject with known allergies or sensitivities to contrast media that cannot be adequately pre-treated prior to the index procedure\n15. Subject with known allergies or sensitivities to nitinol or nickel\n16. Subject is currently enrolled in another investigational device or drug trial that interferes with the study endpoints.\n17. Subject with prior stent(s) within the target vessel, or bypass surgery of or within the target vessel\n18. Subject had previous treatment of the target vessel \\\u003C30 days prior to index procedure\n\nAngiographic exclusion criteria:\n\n1. Angiographic evidence of thrombus within target limb\n2. Inability to obtain antegrade access in the limb from which the Spur can be deployed\n3. Any lesion characteristics, that in the investigator's opinion, would not be amenable to endovascular standard techniques\n4. Significant \\> 50% stenosis of inflow arteries or unsuccessful treatment of inflow lesions\n5. \\> 50% stenosis, flow-limiting dissection (Type D or greater), aneurysm or thrombus of the target lesion following pre-dilation\n6. Inability to obtain additional imaging 15 minutes after target lesion treatment for recoil evaluation.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene. High-risk PAD populations including patients with end-stage renal disease and or diabetes also experience worse outcomes with significantly increased rates of amputation and mortality.\n\nAlthough some patients with PAD are best treated with a combination of medical management, exercise and lifestyle modification, revascularization is indicated in those with advanced stages of disease and particularly in the presence of CLTI. Revascularization of below-the-knee (BTK) arteries is required for most patients suffering from CLTI, but treatment faces numerous challenges comprising calcification, small vessel size, long-lesion length and early elastic recoil. With regard to these challenges, numerous innovative techniques and devices have been developed within the past decades to optimize endovascular treatment of BTK vessels.\n\nThe Spur Peripheral Retrievable Scaffold System (Spur) was developed to directly address many of these pitfalls of infrapopliteal arterial disease. The premise of the design of the Spur is to provide temporary mechanical scaffolding and to prepare the vessel for treatment with a drug-coated balloon (DCB) to enhance drug absorption by creating channels in the endothelium by the deployed Spur.\n\nThe objective of this study is to perform a prospective, single-center, single-arm, non-randomized study to evaluate acute vessel recoil following BTK treatment with the Spur Retrievable Scaffold System in combination with a commercially available DCB in specific patients populations. Specific patient populations that are selected to participate in this study are either at high risk to discover unfavorable outcomes with standard techniques due to a high complexity of lesions and\u002For patients that are not adequately mirrored in available studies. The patient cohorts that will be studied are diabetics and patients on hemodialysis (for at least 6 months). As women are commonly under-represented in comparable trials, this study requires at least 50% of women for each cohort.\n\nThe primary endpoint is vessel recoil within 15 minutes post treatment assessed with angiography. Secondary endpoints will be followed out to 12 months.",[25],"Chronic Limb Threatening Ischemia",[27,28,29,30,31],"vessel recoil","peripheral arterial disease","endovascular revascularization","below-the-knee","chronic limb-threatening ischemia","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":21},"2026-07",{"date":40,"type":21},"2028-09",{"name":42,"class":43},"Medical University of Graz","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":44},"100644508","transfusion-related-changes-in-oxidative-stress-biomarkers-in-neonates-100644508","NCT07672275","Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates","Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates - a Three-Part Prospective Observational Pilot Study","NEO-REDOX","Inclusion Criteria:\n\nPart A:\n\n* Neonates who are monitored on the NICU immediately after birth\n* Written parental informed consent\n\nPart B:\n\n* Term and preterm neonates admitted to the NICU for medical treatment\n* Age ad admission \\\u003C48 hours\n* Written parental informed consent\n\nPart C:\n\n* ELGANs 22(+5)-27(+6) weeks (days) gestation admitted to the NICU\n* Decision to conduct full life support\n* Written parental informed consent\n\nExclusion criteria (Part A, B, C)\n\n* No decision to conduct full life support\n* No parental written informed consent\n* Congenital malformations\n* Family history of hemoglobinopathies (e.g. sickle cell anemia, thalassemia)\n* Fetal anemia requiring in-utero A-RBC transfusions",true,"5 Minutes","5 Months",{"count":57,"type":21},170,"Reactive oxygen species (ROS), which include peroxides, are generated in the human body as by-products of cellular metabolism. In small amounts, they fulfill important physiological functions. However, when produced in excess, they can damage cells and tissues. Extremely low gestation age neonates (ELGANs) are particularly vulnerable to such harmful effects because their antioxidant defense systems are immature, and they are exposed to increased ROS levels due to the oxygen therapy required after birth.\n\nFetal hemoglobin (HbF), the primary oxygen carrier in the blood of newborns, plays a crucial role in this context. Compared with adult hemoglobin (HbA), it has a higher oxygen affinity and a more pronounced pseudoperoxidase activity, which helps protect organs during early development from peroxides.\n\nIn addition to oxygen administration, blood transfusions can also contribute to increased ROS formation. Due to the immature hematopoietic system and the diagnostic blood sampling required, ELGANs frequently receive transfusions with adult red blood cell (A-RBC) concentrates. These lead to a rapid shift from HbF to HbA, further promoting the generation of ROS.\n\nMeasuring ROS in blood is particularly challenging because these molecules are extremely short-lived. Consequently, reference values for newborns are lacking. Therefore, the investigators aim to establish reference ranges for one ROS, the peroxide in both term and preterm healty neonates from birth event onward and to assess the effects of A-RBC transfusions on this parameter in ELGANs.\n\nFurthermore, combining near-infrared spectroscopy-derived measurements of cerebral regional tissue oxygenation with peroxide assessments requiring only minimal blood volumes (0.5 mL per sample) will provide a more comprehensive and quantitatively robust understanding of the physiological changes induced by A-RBC transfusions in ELGANs.\n\nExcessive ROS exposure is considered a key risk factor for severe complications of prematurity, including brain injury, retinopathy, and chronic lung disease. With this project, investigators aim to improve the understanding of these risks and promote new evidence-based strategies in transfusion medicine. In the long term, transfusions with HbF-rich red blood cells derived from cord blood could help reduce ROS formation and provide effective protection for particularly vulnerable preterm infants.",[60,61,62,63],"Oxidative Stress in Neonates","Near Infrared Spectroscopy","Fetal Hemoglobin","Erythrocyte Transfusion",[65,66,67,68,69],"fetal hemoglobin","erythrocyte transfusion","preterm neonates","peroxide","oxidative stress","2026-06-23",{"date":72,"type":36},"2026-06-26",{"date":74,"type":36},"2025-12-12",{"date":76,"type":21},"2028-02-01",{"name":42,"class":43},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100641590","stability-of-blood-clotting-products-stored-in-emergency-ambulances-under-real-world-conditions-100641590","NCT07646964","Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions","Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study","STABLE-EMS","Inclusion Criteria:\n\n* Fibryga samples stored in the participating ground-based EMS ambulance.\n* Octaplas LG AB samples stored in the participating ground-based EMS ambulance.\n* Samples available for laboratory analysis at the predefined study time points.\n* Samples exposed to routine operational storage conditions during the study period.\n\nExclusion Criteria:\n\n* Samples with damaged packaging.\n* Samples with incomplete storage documentation.\n* Samples accidentally removed from the designated storage system during the observation period.\n* Samples unavailable for laboratory analysis.\n* Samples exposed to conditions not representative of routine EMS operation.",{"count":87,"type":21},2,"Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.\n\nThis observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.\n\nThe study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.",[90,91],"Exanguination","Trauma Coagulopathy",[93,94,95,96,97,98],"Prehospital Care","Drug Storage","Temperature Monitoring","Fibrinogen Concentrate","Lyophilized Plasma","Coagulation Products","NOT_YET_RECRUITING","2026-06-15",{"date":102,"type":36},"2026-06-17",{"date":35,"type":21},{"date":105,"type":21},"2026-11-30",{"name":42,"class":43},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100643026","theranovis-dental-gel-in-patients-with-gingivitis-100643026","NCT07641192","Theranovis Dental Gel in Patients With Gingivitis","The Effects of Theranovis Dental Gel in Patients With Gingivitis: A Prospective Pilot Study","Inclusion Criteria:\n\n* Male and female participants aged over 18 years\n* At least 12 teeth per jaw (natural teeth, including restorations such as crowns and implants)\n* Smokers (less than 10 cigarettes per day)\n* Gingivitis with intact periodontium (probing depth ≤ 3.0 mm, bleeding on probing \\> 10%)\n* Gingivitis with intact periodontium (probing depth ≤ 4 mm, no bleeding on probing at these sites)\n* Periodontal screening index (PSI) up to grade 2\n\nExclusion Criteria:\n\n* Male and female participants under 18 years of age\n* Fewer than 12 teeth per jaw\n* Individuals not capable of giving informed consent\n* Individuals with hypersensitivity or allergies to any of the study product ingredients\n* Patients with periodontitis\n* Patients with non-plaque-induced gingivitis\n* Periodontal screening index (PSI) grade 3 or higher\n* Current antibiotic prophylaxis",{"count":115,"type":21},20,"INTERVENTIONAL",[118],"NA","The aim of this randomized, blinded, controlled study is to compare the theranovis dental gel with a placebo product in order to determine whether an improvement in oral health can be achieved in patients with gingivitis.",[121,122],"Gingivitis","Oral Health Care",[124,125],"theranovis dental gel","gingivitis","2026-06-08",{"date":128,"type":36},"2026-06-11",{"date":130,"type":21},"2026-06",{"date":132,"type":21},"2027-04",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":116,"phases":144,"briefSummary":145,"conditions":146,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":44},"100613469","exercise-and-the-immune-response-in-lung-cancer-100613469","NCT07267000","EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER","ImmuEX","Inclusion Criteria:\n\n* Patients suffering from non-small cell or small-cell lung cancer of any histologic subtype, irrespective of routine treatment regimen\n* ECOG 0 or 1\n\nExclusion Criteria:\n\n* Kachexia (BMI\\\u003C18.5)\n* instable bone metastases\n* orthopedic condition rendering the patient unable to ride a stationary bike\n* any medical contraindication for exercise and training\n* a living will against basic or advanced life support","75 Years",{"count":143,"type":21},50,[118],"This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell and small-cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment. It has widely been accepted that exercise strongly impacts immune response, and might influence antitumor immune response as well. In this study, patients suffering from lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The immunologic response, i.e. cytokine profiles and changes in peripheral blood mononuclear cell (PBMC) characteristics will be the main endpoint. Blood will be taken from the patients at different timepoints, and blood samples will be tested for these immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.",[147,148,149,150],"Non-Small Cell Lung Cancer","Exercise Training","Immunotherapy","Small Cell Cancer Of The Lung",[152,153,149,154,155],"Non-small cell lung cancer","Exercise","Outcome","Small-cell lung cancer",{"date":157,"type":36},"2026-06-09",{"date":159,"type":36},"2026-04-01",{"date":161,"type":21},"2029-05-01",{"name":42,"class":43},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":44},"100643799","urinary-microbiome-as-a-biomarker-for-melanoma-diagnosis-and-response-prediction-to-systemic-tumour-therapy-100643799","NCT07635732","Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy","The Potential of the Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy, a Pilot Study","Inclusion Criteria:\n\n* melanoma with indication for systemic therapy\n* age above 18\n* informed consent\n\nExclusion Criteria:\n\n* \\- inability to provide informed consent\n* antibiotic use (except for topical use) ≤ 8 weeks prior to screening\n* consumption of probiotic or prebiotic supplements within 4 weeks prior to screening\n* current diagnosis of any disease with systemic inflammation (e.g. cellulitis, herpes zoster, psoriasis, etc.)\n* for the case group: diagnosis of any active malignancy other than melanoma (except for basal cell carcinoma)\n* for the control group: diagnosis of any active malignancy (except for basal cell carcinoma)",{"count":143,"type":21},"This study looks at whether the bacteria naturally present in urine (the \"urinary microbiome\") can help doctors better understand melanoma, a type of skin cancer, and predict how well patients respond to treatment.\n\nIn recent years, researchers have discovered that bacteria in the body-especially in the gut-can influence cancer development and how patients respond to therapy. However, very little is known about the bacteria in urine and whether they may also play a role in cancer.\n\nIn this study, patients with melanoma who are starting treatment (such as immunotherapy or targeted therapies) will be asked to provide urine samples and stool samples at several time points, as well as answer questionnaires about their health and lifestyle. A group of people without melanoma will also provide urine samples for comparison.\n\nResearchers will analyze these samples to identify the types of bacteria present and how they change over time. They will then investigate whether certain bacterial patterns are linked to better or worse treatment outcomes.\n\nThe study does not change the medical treatment patients receive. Participation mainly involves providing samples and filling out questionnaires, which represents only a small additional effort.\n\nThe results of this study may help to identify new, non-invasive biomarkers that could improve early diagnosis and help doctors choose the most effective treatment for melanoma patients in the future",[173],"Melanoma Stage IV",[175,176,177,178,179,180,181],"microbiome","urinary microbiome","gut microbiome","sequencing","prediction","response","systemic therapy","2026-06-03",{"date":157,"type":36},{"date":185,"type":36},"2025-05-08",{"date":187,"type":21},"2030-05",{"name":42,"class":43},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":116,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100619861","bis-in-icu-interventional-study-100619861","NCT07350122","BIS in ICU Interventional Study","Effect of BIS-Guided Sedation on Clinical Outcomes in Postoperative Cardiac Surgery ICU Patients: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing cardiac surgery with subsequent admission to the intensive care unit (e.g., valve surgery, coronary artery bypass grafting, aortic surgery)\n* Planned or expected duration of invasive mechanical ventilation \\> 6 hours postoperatively\n* Requirement for continuous sedation during ICU stay\n\nExclusion Criteria:\n\n* Pre-existing neurological disorders affecting consciousness or sedation assessment (e.g., severe dementia, epileptic encephalopathy).\n* Acute neurological events in the perioperative period (e.g., stroke, intracranial hemorrhage).\n* Severe hepatic dysfunction (Child-Pugh Class C).\n* Participation in another interventional study potentially affecting sedation or cognitive outcomes.\n* Pregnancy or lactation.\n* Do-not-intubate (DNI)\u002FDo-not-resuscitate (DNR) orders or documented limitation of therapy.\n* Patients in whom short-term survival is deemed unlikely due to the clinical course.",{"count":197,"type":21},144,[118],"This study will test whether using a Bispectral Index (BIS) monitor to guide sedation can reduce the amount of sedative medication given to adults in the intensive care unit (ICU) after cardiac surgery. BIS is a non-invasive, EEG-based monitor that shows a number from 0-100 to reflect level of consciousness. Researchers will compare BIS-guided sedation to standard sedation guided by clinical scales (such as the Richmond Agitation-Sedation Scale, RASS).\n\nAbout 144 participants will be randomly assigned (1:1) to one of two groups at two hospitals in Austria (Medical University of Graz and Klinikum Wels-Grieskirchen). In the BIS group, clinicians will use BIS values and standard care to titrate sedation and will aim to avoid sustained BIS values below 50. In the control group, sedation will follow standard practices using clinical scales; BIS will be recorded but hidden from caregivers. The trial is open-label for treating staff; outcome assessors and data analysts will be blinded.\n\nParticipants will be in the study during their ICU sedation and mechanical ventilation period (typically more than 6 hours), with follow-up through ICU and hospital discharge. The primary outcome is the time-averaged dose of propofol (mg\u002Fkg\u002Fh) given during continuous ICU sedation until weaning (up to 72 hours). Secondary outcomes include duration of ventilation and sedation, depth of sedation measures, sedative and catecholamine doses, pulmonary infections (including ventilator-associated pneumonia), ICU and hospital length of stay, delirium, and in-hospital mortality.\n\nRisks are minimal and may include mild skin irritation from forehead electrodes. Possible benefits include improved sedation management; benefits are not guaranteed. Taking part is voluntary.",[201,202,203,204,205],"Cardiac Surgical Procedures (Postoperative Population)","Critical Illness","Postoperative Complications (Cardiopulmonary)","Delirium - Postoperative","Pneumonia, Ventilator-Associated","2026-05-28",{"date":208,"type":36},"2026-05-29",{"date":38,"type":21},{"date":211,"type":21},"2027-06",{"name":42,"class":43},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":116,"phases":224,"briefSummary":225,"conditions":226,"keywords":232,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100634808","xr2esilience---xr-based-resilience-training-for-stress-and-mental-health-in-healthcare-workers-100634808","NCT07544498","XR2ESILIENCE - XR-Based Resilience Training for Stress and Mental Health in Healthcare Workers","A Pragmatic Randomized Controlled Trial Study Protocol: XR2ESILIENCE - Pioneering XR Technology for the Promotion of Resilience and Mental Health of the Healthcare Workforce","XR2ESILIENCE","Inclusion Criteria:\n\n1. working as a nurse in direct patient care within a clinical setting;\n2. working at least 10h\u002Fweek in their profession;\n3. speaking the language in which the RCT is conducted sufficiently well;\n4. able and willing to participate in all aspects of the study;\n5. understanding and signing the appropriate informed consent form.\n\nExclusion Criteria:\n\n1. a diagnosed severe mental disorder associated with alterations in reality perception (e.g., delusions, hallucinations, derealization, depersonalization, or dementia), including in particular schizophrenia, bipolar disorder, severe major depressive disorder, or other psychotic disorders (lifetime);\n2. a current major depressive episode or a current post-traumatic stress disorder (PTSD);\n3. an acute or clinically significant medical condition that may interfere with the safe use of an XR headset or study participation, including but not limited to epilepsy, pronounced dizziness, balance disorders, or acute cardiovascular conditions;\n4. an acute eye infection (e.g., conjunctivitis);\n5. unstable medication related to a mental health condition, defined as recent changes in dosage or class of psychotropic medication;\n6. initiation of psychotherapy or any structured stress-management training within the past three months.","65 Years",{"count":223,"type":21},232,[118],"This study investigates the effectiveness of an extended reality (XR) based resilience training program designed to support the mental health and well-being of nurses working in hospital settings. Nurses are exposed to high emotional, cognitive, and organizational demands and show elevated levels of work-related stress and stress-associated mental health problems. Strengthening resilience and coping capacities is therefore an important preventive approach to support nurses' well-being and sustain quality of care.\n\nThe study is conducted as a pragmatic randomized controlled trial with a waitlist control group and includes approximately 232 nurses from hospitals in several European countries. Participants are randomly assigned either to an XR-based resilience training group or to a waitlist control group that continues with care as usual during the waiting period. The XR-based intervention consists of eight immersive training sessions delivered over approximately ten weeks using a head-mounted display. The training focuses on behavioral, cognitive, and emotional coping strategies and aims to enhance key resilience factors such as problem-solving, cognitive reappraisal, emotion regulation, and positive self-care.\n\nThe primary outcome is perceived stress, assessed using the Perceived Stress Scale. Secondary outcomes include resilience, occupational self-efficacy, quality of life, psychological distress, burnout symptoms, coping strategies, work-related rumination, and turnover intentions. Assessments are conducted at baseline, post-intervention, and at a 20-week follow-up. In addition, a subgroup of participants will optionally provide physiological data during selected XR sessions to explore digital biomarkers related to stress and recovery.\n\nThe findings of this study will provide evidence on the effectiveness, feasibility, and acceptance of XR-based resilience training for nurses and inform future implementation of digital mental health interventions in healthcare workplaces.",[227,228,229,230,231],"Occupational Stress","Work-Related Stress","Mental Health","Burnout","Resilience",[233,234,235,236,237,238,239,240,241,242,243,244],"Extended Reality","Virtual Reality","XR-based Intervention","Resilience Training","Stress Reduction","Nurses","Healthcare Workers","Occupational Health","Mental Well-Being","Digital Mental Health","Preventive Intervention","Randomized Controlled Trial","2026-05-13",{"date":247,"type":36},"2026-05-18",{"date":249,"type":21},"2026-09",{"date":251,"type":21},"2028-03",{"name":42,"class":43},8,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":116,"phases":266,"briefSummary":268,"conditions":269,"keywords":276,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":44},"100613069","phase-4-duration-of-surfactant-administration-and-impact-on-stabilisation-of-vital-parameters-in-very-preterm-neonates-1-minutes-versus-5-minutes-100613069","NCT07261787","Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes","Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minute Versus 5 Minutes - a Prospective Randomised-controlled Phase IV Trial - A Randomised Clinical Trial on Influence of Duration of Surfactant Administration on Stabilisation of Routine Monitoring Parameters and Cerebral Tissue Oxygen Saturation Monitoring in Preterm Neonates \u003C 28 Weeks of Gestational Age","SurfStab I","Inclusion Criteria:\n\n* Preterm neonate \\\u003C28+0 weeks (gestational age up to 27 weeks and 6 days)\n* Indication of surfactant administration via the LISA method\n* Postnatal age \\\u003C 72 hours\n\nExclusion Criteria:\n\n* Invasive ventilation, indication of INSURE procedure\n* Severe pulmonary or cardiac malformation affecting oxygenation or congenital cerebral malformation\n* Preexisiting diagnose of any IVH \\> grade 2 or PVH.","0 Months","72 Hours",{"count":265,"type":21},76,[267],"PHASE4","Respiratory distress syndrome (RDS) is common in very preterm infants due to surfactant deficiency. Surfactant replacement therapy is lifesaving, and current guidelines recommend the less invasive surfactant administration (LISA) technique. However, the optimal duration of surfactant instillation during LISA has never been systematically evaluated. Rapid instillation may provoke transient hypoxia and bradycardia, while slower administration might improve physiological stability and cerebral oxygenation.\n\nThis randomised controlled trial investigates whether the duration of surfactant administration (1 minute versus 5 minutes) affects cerebral and systemic oxygen stability in extremely preterm neonates (\\\u003C 28 weeks).",[270,271,272,273,274,275],"Neonates and Preterm Infants","Infant Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal","Surfactant","Cerebral Oxygenation","Cerebral Oxygen Saturation",[277,278,279,280,67,281,282],"surfactant","surfactant administration","LISA","less-invasive surfactant administration","cerebral oxygenation","near-infrared spectroscopy","2026-05-12",{"date":285,"type":36},"2026-05-14",{"date":287,"type":36},"2026-02-20",{"date":289,"type":21},"2028-12-01",{"name":42,"class":43},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":299,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":303,"conditions":304,"keywords":311,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":44},"100601389","the-peripheral-muscle-oxygenation-and-perfusion-score-as-a-new-non-invasive-tool-to-predict-elevations-in-c-reactive-protein-levels-in-neonates-100601389","NCT07109856","The Peripheral(-Muscle) Oxygenation and Perfusion Score as a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates","The Peripheral(-Muscle) Oxygenation and Perfusion Score (POPScore) a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates - a Prospective Phase II Observational Study","POP-Score","Inclusion Criteria:\n\n* birth weight ≥ 2000 grams\n* Signs of respiratory distress at time-point of inclusion (tachypnoea \\>60\u002Fmin, grunting, intercostal\u002Fsubcostal\u002Fjugular retractions, nasal flaring, supplemental oxygen or respiratory support)\n* Decision to conduct full life support\n* Written informed consent obtained within the first 6 hours after birth, before inclusion in the study\n* Age \\\u003C 6 hours\n\nExclusion Criteria:\n\n* No decision to conduct full life support\n* No written informed consent\n* Birth weight \\\u003C 2000 grams\n* Age \\> 6 hours\n* Severe congenital malformations,\n* Umbilical cord artery pH \\\u003C7.20","0 Hours","6 Hours",{"count":302,"type":21},93,"This is a prospective, single-center Phase II observational study investigating the predictive value of the \"Peripheral(-muscle) Oxygenation and Perfusion Score\" (POP-Score), a novel non-invasive composite index, for early detection of infection\u002Finflammation in neonates. The POP-Score combines peripheral muscle oxygenation measured via near-infrared spectroscopy (NIRS) with routinely monitored clinical parameters (heart rate, oxygen saturation, systolic blood pressure, and subcutaneous fat thickness). The study aims to determine the optimal cut-off value of the POP-Score measured within the first 6 hours after birth to predict elevated C-reactive protein (CRP ≥20 mg\u002FL) within 48 hours. Additionally, multi-site NIRS measurements (cerebral, peripheral muscle, intestinal, and flank) will be evaluated to assess their association with inflammation. The study includes term and moderate-to-late preterm neonates (birth weight ≥2000g) with respiratory distress, admitted to the neonatal intensive care unit at the Medical University of Graz.",[305,306,61,307,308,309,310],"Prematurity, Infections","NIRS","Preterm Neonates","Term Infant","Infection","Neonatal Sepsis, Early-Onset",[306,282,297,312,67],"neonates",{"date":285,"type":36},{"date":315,"type":36},"2025-11-27",{"date":317,"type":21},"2028-05-01",{"name":42,"class":43},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":116,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":44},"100640262","the-effect-of-psychoeducational-diagnosis-communication-on-perception-of-illness-satisfaction-and-behavioral-intentions-among-patients-with-functional-neurological-movement-disorders-100640262","NCT07588282","The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intentions Among Patients With Functional Neurological Movement Disorders","The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intentions in Patients With Functional Neurological Movement Disorders: An Intervention Study Using a Within-Subject Design","Inclusion Criteria:\n\n* Presence of any of the following functional movement disorders:\n\n  * Functional paralysis\n  * Functional seizures\n  * Functional tremor\n  * Functional drop attacks\n  * Functional dystonia\n  * Functional twitching\n  * Functional facial symptoms\n  * Functional tics\n  * Functional parkinsonism\n\nExclusion Criteria:\n\n* The patient is unable to give informed consent.\n* The patient is temporarily unable to give informed consent.\n* The patient does not have sufficiently understand German language to answer the questionnaires (the questionnaires are available only in German).","80 Years",{"count":328,"type":21},35,[118],"Functional neurological movement disorders are common conditions that can lead to significant limitations in daily life. They result from a functional disorder in the brain. A clear, understandable, and empathetic explanation of the diagnosis is a crucial first step in treatment. The purpose of this clinical study is to investigate how a clear and detailed explanation of the diagnosis of functional neurological movement disorders affects patients' understanding of their condition and their symptoms The investigators are interested in how well patients understand the diagnosis and the symptoms they experience as the disease progresses, as well as how the conversation between patient and doctor is experienced from both perspectives. In addition, as part of the study, a one-time examination using brain imaging (magnetic resonance imaging) will be conducted to better understand possible differences in brain function.",[332,333],"Functional Neurological Disorder","Functional Movement Disorder","2026-05-11",{"date":285,"type":36},{"date":337,"type":36},"2026-03-31",{"date":339,"type":21},"2027-12-31",{"name":42,"class":43},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":349,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":352,"studyType":22,"phases":4,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":44},"100632428","preeclampsia-origin-characteristics-and-effects-on-mother-and-baby-100632428","NCT07513558","Preeclampsia: Origin, Characteristics and Effects on Mother and Baby","Face to Face With Preeclampsia: Understanding Its Origin, Characteristics and Effects on Mother and Baby","GRAZ-PE","Inclusion Criteria:\n\n* Ongoing pregnancy with preeclampsia regardless the gestational age diagnosed for PE\n\nExclusion Criteria:\n\n* Maternal or fetal genetic abnormalities","FEMALE",{"count":351,"type":21},250,"12 Weeks","Preeclampsia (PE) is a serious pregnancy complication characterized by new-onset hypertension and signs of maternal organ dysfunction, often accompanied by placental abnormalities and systemic endothelial dysfunction. PE is associated with adverse maternal and perinatal outcomes and confers an increased long-term risk of cardiovascular and metabolic disease for both mother and offspring.\n\nThis prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with preeclampsia. Pregnant women with a clinical diagnosis of PE according to current obstetric guidelines will be recruited at their initial presentation either in the in- or outpatient clinic or in the delivery ward, respectively and followed through late pregnancy, delivery, and early postpartum.\n\nParticipants will undergo study visits during pregnancy, sample collection at delivery, and a postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of pregnancies complicated by preeclampsia.\n\nData and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of preeclampsia-associated biological and clinical changes.",[355,356],"Preeclampsia (PE)","Pregnancy","2026-04-09",{"date":359,"type":36},"2026-04-13",{"date":361,"type":36},"2026-03-01",{"date":363,"type":21},"2036-03",{"name":42,"class":43},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":349,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":44},"100628305","gestational-diabetes-and-health-outcomes-in-mothers-and-babies-100628305","NCT07459907","Gestational Diabetes and Health Outcomes in Mothers and Babies","Understanding the Effects of Gestational Diabetes on Mother and Baby","GRAZ-GDM","Inclusion Criteria:\n\n* ongoing pregnancy prior to the 32nd gestational week and a positive GDM screening\n\nExclusion Criteria:\n\n* gestational age 32nd gestational week\n* fetal genetic anomalies \u002Fmalformation",{"count":374,"type":21},400,"Gestational diabetes mellitus (GDM) is a common pregnancy complication characterized by impaired glucose metabolism and increased insulin resistance. GDM is associated with adverse pregnancy outcomes and an increased long-term risk of metabolic and cardiovascular disease for both mother and offspring.\n\nThis prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with GDM. Pregnant women with a positive 75 g oral glucose tolerance test (OGTT) between gestational weeks 24 and 28 will be recruited after diagnosis and followed through late pregnancy, delivery, and early postpartum.\n\nParticipants will undergo two study visits during pregnancy, sample collection at delivery, and one postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of GDM pregnancies.\n\nData and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of GDM-related changes.",[377,356],"Gestational Diabetes Mellitus (GDM)",[379,380,381,382,383,384,385,356,386,387,388,389],"GDM","Insulin resistance","Glucose metabolism","Cardiometabolic risk","Pregnancy outcomes","Pregnancy phenotyping","Maternal and infant health","Post-partum follow up","Longitudinal cohort","Fetal growth","Neonatal adiposity",{"date":359,"type":36},{"date":392,"type":36},"2025-06-15",{"date":394,"type":21},"2035-06",{"name":42,"class":43},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":53,"sex":349,"minAge":18,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":406,"conditions":407,"keywords":411,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":44},"100587240","pregnancy-cohort-study-pregnancy-as-a-window-to-future-health-100587240","NCT06925815","Pregnancy Cohort Study: Pregnancy as a Window to Future Health","PregWin","Inclusion Criteria:\n\n* ongoing pregnancy prior to 14th gestational week, women with child wish; above 18 years of age, giving informed consent\n\nExclusion Criteria:\n\n* gestational age \\> 14th week of gestation; below 18 years of age; fetal genetic anomalies \u002Fmalformation","50 Years",{"count":405,"type":21},800,"The goal of this observational cohort study is to gain deep insights into how metabolic disorders such as obesity or diabetes during pregnancy affect the metabolic and cardiovascular health of mother and child in the short and long term.\n\nIt will investigate the following questions:\n\n* How do maternal metabolic disorders affect pregnancy outcomes?\n* How do maternal metabolic disorders affect fetal growth?\n* How do maternal metabolic disorders affect the newborn's metabolism and body composition?\n* How do maternal metabolic disorders during pregnancy affect breast milk composition?\n* How do maternal metabolic disorders during pregnancy affect the metabolic health of the mother after birth? Participants in this study are pregnant women who will be asked to come to the clinics for three visits during their pregnancy, as well as for the delivery of their baby, and one time 2-3 months thereafter. At each visit, researchers will perform physical examinations (such as body composition measurements) and collect biological samples (blood, urine, saliva), clinical information, and lifestyle data. At birth, researchers will collect cord blood and breast milk as well as clinical data of the delivery and the health of the baby. Researchers will measure body fat in newborn babies and at 2-3 months of age.",[408,409,410],"Healthy Pregnant Women","Obese Pregnant Women","Gestational Diabetes",[412,413,414,415,416,417,418,419,420,421,422],"pregnancy","deep phenotyping","maternal metabolism","body composition","longitudinal pregnancy cohort study","fetal growth","obesity in pregnancy","neonatal adiposity","gestational weight gain","gestational diabetes","cardiovascular health",{"date":359,"type":36},{"date":425,"type":36},"2023-07-27",{"date":427,"type":21},"2034-06",{"name":42,"class":43},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":44},"100631251","collagen-fingerprinting-for-stratification-of-pulmonary-hypertension-ph-patients-100631251","NCT07498244","Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients","Inclusion criteria:\n\nPatients undergoing lung transplantation with COPD or PF, with or without associated PH and PAH.\n\n\\- Outpatient cohort with COPD or PF, with or without associated PH or PAH.\n\nExclusion criteria:\n\n* Presence of other lung diseases\n* Signs of infection, such as pneumonia, pulmonary tuberculosis, or pleural effusions.",{"count":5,"type":21},"Chronic lung diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension. This serious complication involves increased pressure in the lung vessels, which strains the heart and worsens outcomes. Since the early symptoms are unclear, diagnosis often occurs too late, underscoring the need for simple, noninvasive methods of early detection.\n\nA key driver of the disease is vascular remodeling, which involves the narrowing and stiffening of blood vessels. This process involves changes in the extracellular matrix, particularly in the understudied basement membrane. Our project examines how specific components, especially non-classical collagens, change during disease progression. As vessels remodel, detectable fragments enter the bloodstream, potentially creating a molecular fingerprint of the disease.\n\nBy analyzing lung tissue and blood samples, the investigators aim to identify non-invasive biomarkers for earlier diagnosis, better patient classification, and more personalized treatment.",[438],"Pulmonary Hypertension Due to Lung Diseases",[440],"Collagens","2026-03-30",{"date":443,"type":36},"2026-04-03",{"date":35,"type":21},{"date":446,"type":21},"2030-06-30",{"name":42,"class":43},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":44},"100630834","clinical-applicability-of-liquid-biopsy-in-chondrosarcoma-100630834","NCT07492823","Clinical Applicability of Liquid Biopsy in Chondrosarcoma","Clinical Applicability of Liquid Biopsy in Intermediate and Malignant Cartilaginous Neoplasms - A Prospective Cohort Study","Inclusion Criteria:\n\n* Semimalignant or malignant cartilaginous tumour (atypical cartilaginous tumour, chondrosarcoma G1\u002F2\u002F3, dedifferentiated chondrosarcoma)\n* Definite surgery of primary tumour\n\nExclusion Criteria:\n\n* Prior tumour-specific treatment (except for biopsy)","99 Years",{"count":457,"type":21},60,"Treatment of intermediate (i.e. atypical cartilaginous tumour, ACT) and malignant cartilaginous tumours (i.e. chondrosarcoma) involves surgical resection, while effects of systemic therapies are limited. Thus, it is of importance to diagnose these tumours timely, estimate their prognosis, and detect recurrences at early stages. Apart from diagnosis and disease monitoring with cost-intensive, as well as ionizing radiation-exposing imaging modalities, liquid biopsy constitutes a potent, non-invasive diagnostic, prognostic and predictive tool in oncology. Intermediate\u002Fmalignant cartilaginous neoplasms are known to frequently harbour specific mutations, as Isocitrate dehydrogenase 1\u002F2 (IDH1\u002F2). These may well be detectable with liquid biopsy, a non-invasive diagnostic measure. Further, other genetic alterations found in primary tumour tissue as well as cytokines\u002Fchemokines may be of additive diagnostic and prognostic value.\n\nThis prospective cohort study aims at answering 4 questions: 1) Possibility to differentiate between ACT and higher-grade chondrosarcoma by measuring mutant IDH1\u002F2 circulating free DNA (cfDNA) in blood stream; 2) Feasibility to detect recurrences during follow-up by monitoring mutant IDH1\u002F2 cfDNA; 3) Prognostic potential of high mutant IDH1\u002F2 cfDNA levels; 4) Additive diagnostic\u002Fprognostic value of other genetic alterations found in primary tumour tissue as well as cytokine profiling.\n\nOver 2 years, an estimated 60 patients with intermediate\u002Fmalignant cartilaginous tumours will meet the inclusion criteria. At 11 time points (preoperatively, postoperatively, after 6 weeks, as well as 3, 6, 9, 12, 15, 18, 21 and 24 months), blood samples will be ascertained. The following methodological steps will be carried out: 1) next generation sequencing of primary tumour tissue towards IDH1\u002F2 mutations (and further genetic alterations); 2) selection of digital droplet polymerase chain reaction (ddPCR) assays with patient-specific probes; 3) blood sample collection; 4) cfDNA extraction from blood samples; 5) Quantification of mutant IDH1\u002F2 cfDNA with ddPCR; 6) cytokine and chemokine profiling in blood samples. Patients will be followed-up for 2 years, resulting in an overall study period of 4 years.\n\nThis study may help to elucidate the role of liquid biopsy in diagnosis and follow-up of patients with chondrosarcoma.",[460],"Chondrosarcoma of the Bone",[462,463,464,465],"chondrosarcoma","liquid biopsy","chemokine profiling","atypical cartilaginous tumour","2026-03-19",{"date":468,"type":36},"2026-03-25",{"date":470,"type":21},"2026-06-01",{"date":472,"type":21},"2030-05-31",{"name":42,"class":43},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":116,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":44},"100625179","comparison-of-customized-allogenic-versus-autogenous-bone-block-graft-for-alveolar-ridge-augmentation-100625179","NCT07419269","Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation","IndiALLO","INCLUSION CRITERIA\n\n* 1-4 missing teeth that need to be replaced with dental implants\n* Bone ridge width insufficient for dental implant placement; \\\u003C5 mm of width as measured in a cone beam computed tomography at the ideal prosthetic position\n* Medically healthy with no known allergies to antibiotics\n* Non-smoker or light smoker (\\\u003C 10) or previous smoker who had quit for 5 years or more\n* Periodontal health, as confirmed by clinical examination (Full mouth bleeding score and full mouth plaque score \\\u003C 25%) and at least one neighboring natural tooth to the defect site(s)\n* Age of 18 or above\n\nEXCLUSION CRITERIA\n\n* All contraindications against implant treatment or augmentative procedures (e.g., advanced systemic diseases, corticosteroid medication, immunodeficiency, pregnancy, intention to become pregnant, breastfeeding, lack of safe contraception)\n* Treatments or diseases that may have an effect on bone turnover or the bone itself or non-mineralized tissue metabolism (e.g., bisphosphonates or local radiotherapy, skeletal immaturity)\n* Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone diseases\n* Any active malignancy or patient undergoing treatment for a malignancy Study protocol: IndiALLO Version 4\u002F19.03.2025 Page 9 von 32\n* Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to class of drugs or the investigational product\n* Persistent compartment syndrome or neurovascular residua of compartment syndrome",{"count":482,"type":21},26,[118],"The aim of this study is to determine whether jawbone augmentations using allogeneic and autogenous bone blocks lead to comparable three-dimensional clinical and radiological outcomes.\n\nIn addition, the study seeks to investigate whether there are differences regarding safety, biocompatibility, complications, and PROMs.\n\nFurthermore, it aims to clarify whether differences exist between the two groups with respect to implant condition (one year after implantation and during annual follow-ups for up to five years).",[486],"Alveolar Bone Loss","2026-02-16",{"date":489,"type":36},"2026-02-18",{"date":491,"type":36},"2025-04-01",{"date":493,"type":21},"2032-08-01",{"name":42,"class":43},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":116,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":516,"leadSponsor":518,"locationsCount":44},"100615823","3d-liver-volumetry-100615823","NCT07297615","3D Liver Volumetry","Accuracy of Individualized 3D Reconstruction in Predicting Liver Resection Volume: A Prospective Study","Inclusion Criteria:\n\n* Adult patients (≥18 years) undergoing open or minimally invasive major liver resection at the Clinical Division of General, Visceral and Transplant Surgery who provide written informed consent prior to participation will be included.\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent will be excluded.\n* Minor resections.\n* Contraindications to MRI.",{"count":7,"type":21},[118],"The study aims to improve preoperative evaluation of liver resection volume in patients undergoing major hepatectomies. Accurate prediction of the planned resection and the future liver remnant (FLR) is critical to minimize the risk of postoperative liver failure, which is associated with increased morbidity and mortality. Conventional imaging-based volumetry may have limited accuracy. This study investigates the use of individualized 3D liver models combined to enhance visualization and volumetric analysis of liver anatomy and resection boundaries.\n\nPatients are recruited in the liver outpatient clinic and, upon consent, preoperative 3D models are created using Medics 3D. During surgery, the planned resection is guided by the individualized 3D models. Postoperatively, the resected specimen undergoes CT-based volumetry to compare the predicted resection volume from the 3D model with the actual volume. Routine postoperative follow-up is conducted. The study aims to optimize surgical planning, enhance the accuracy of future liver remnant prediction.",[506,507,508,509,510,511],"Liver Surgery","Liver Cancer","Surgical Planning","Liver","Volumetric Analysis","3D-reconstruction","2026-02-13",{"date":514,"type":36},"2026-02-17",{"date":159,"type":21},{"date":517,"type":21},"2028-09-30",{"name":42,"class":43},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":526,"minAge":18,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":539,"locationsCount":4},"100621859","liquid-biopsy-in-germ-cell-tumors-100621859","NCT07376096","Liquid Biopsy in Germ Cell Tumors","Diagnostic and Prognostic Value of Liquid Biopsy in Germ Cell Tumors","Inclusion Criteria:\n\n* Male patients with the age ≥ 18years with\n* Seminomatous or non-seminomatous germ cell tumors (extragonadal origin is allowed)\n* Metastatic disease\n* Stage I patients on active surveillance (for seminoma patients at least one risk factor, rete testis infiltration or tumor size \\> 4cm, should be present)\n\nExclusion Criteria:\n\n* Other tumors than germ cell tumors of the testis\n* Patients with a second malignancy within the last 5 years (except germ cell tumors)\n* Stage I patients who received adjuvant treatment","MALE",{"count":528,"type":21},200,"Theoretical framework: Testicular germ cell tumors (TGCT) are characterized by frequent chromosomal anomalies such as gain of chromosome 12p and low rates of somatic mutations. Cell-free circulating tumor DNA (ctDNA) has been investigated in some cancers but only a few studies explored the presence of ctDNA in TGCT. The consistent gain of genetic material from chromosome 12p makes TGCT patients to ideal candidates for liquid biopsy investigations. We have analyzed three pre-chemo samples with our plasma-Seq approach and applied the ichorCNA algorithm to call for somatic copy number alterations (SCNA) and estimate the tumor fraction. Besides the frequently observed chromosome 12p gain, a variety of other SCNA were detected indicating that shallow whole genome sequencing (sWGS) is a suitable approach to analyze ctDNA in TGCT. Only 60% of TGCT patients express the classical markers alpha fetoprotein (AFP) and beta (human chorionic gonadotropin) HCG. Biomarkers to monitor patients who don't express the classical markers are of great need.\n\nHypotheses: We postulate that tumor-specific aberrations can be detected non-invasively in plasma DNA from patients with metastatic TGCT and serve as a diagnostic tool. Furthermore, we will investigate if the change of ctDNA during curative treatment can be used as monitoring tool and allows risk classification in comparison to conventional markers and the novel micro RNA biomarker miR-371a-3p (prognostic value of ctDNA).\n\nMethods: For ctDNA and micro RNA analysis, blood samples will be drawn from patients before orchiectomy, before chemotherapy start, prior to the second cycle of chemotherapy, after completion of treatment and in case of relapse. In order to identify SCNA and to estimate the tumor content in plasma we will employ sWGS and analyze the data with the ichorCNA algorithm for a detection of SCNA. Since TGCT have low rates of somatic mutations, orchiectomy samples from patients with disease recurrence and plasma samples at time of recurrence will also be compared with the Biomodal platform which allows analysis of genetic as well as epigenetic changes.",[531,532],"100 Stage I Patients","100 Metastatic Patients","2026-01-22",{"date":535,"type":36},"2026-01-29",{"date":487,"type":21},{"date":538,"type":21},"2030-02-15",{"name":42,"class":43},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":550,"conditions":551,"keywords":554,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":565},"100600848","clinical-registry-for-the-characterization-of-the-pulmonary-vascular-phenotype-in-patients-with-chronic-obstructive-pulmonary-disease-100600848","NCT07102823","Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease","Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease - a Retrospective Multi-center Data Analysis","COPD-PH","Inclusion Criteria:\n\n* clinical diagnosis of COPD\n* right heart catheterization including mPAP (Mean Pulmonary Artery Pressure), PVR (Pulmonary Vascular Resistance), PAWP (Pulmonary Artery Wedge Pressure), CO (cardiac output)\n* age \\>= 18 years\n\nExclusion Criteria:\n\n* pediatric patients\n* no COPD or no RHC",{"count":549,"type":21},1000,"Registry of COPD (Chronic Obstructive Pulmonary Disease) patients who underwent right heart catheterization (RHC) and full clinical evaluation for pulmonary hypertension",[552,553],"Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Hypertension",[555,556,557],"pulmonary hypertension","chronic obstructive pulmonary disease","right heart catheterization","2026-01-13",{"date":560,"type":36},"2026-01-14",{"date":562,"type":36},"2025-09-01",{"date":339,"type":21},{"name":42,"class":43},3,{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100416830","database-for-interstitial-lung-disease-100416830","NCT04707781","Database for Interstitial Lung Disease","Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* patients with a known systemic disease bearing a risk for ILD\n* signed informed consent (for prospective part)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)",{"count":574,"type":21},412,"The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.",[577],"Lung Diseases, Interstitial",{"date":579,"type":36},"2026-01-15",{"date":581,"type":36},"2021-05-01",{"date":583,"type":21},"2029-01-31",{"name":42,"class":43},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":44},"100179231","database-for-clinical-and-anamnestic-data-in-pulmonary-hypertension-100179231","NCT01607502","Database for Clinical and Anamnestic Data in Pulmonary Hypertension","Inclusion Criteria:\n\n* patients with pulmonary hypertension\n* patients at risk for getting pulmonary hypertension\n* patients who have symptoms which my be due to pulmonary hypertension when we have their written informed consent.\n\nExclusion Criteria:\n\n* patients without written informed consent",{"count":592,"type":21},900,"Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization.\n\nThere are different forms of PH defined in the classification of Dana Point 2008.\n\nPH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like the echocardiography, stress echocardiography and cardio pulmonary exercise testing. In the diagnosis process and in the follow up of PH patients biomarkers like NTproBNP are helpful. There are no specific biomarkers for the disease which can make the diagnosis process easier and predict prognosis.\n\nThe systematic data collection in a data base provides better information about patients in daily routine and clinical studies as well as in the design of new studies.",[553],[596,597,598],"Pulmonary hypertension","database","biomarker",{"date":579,"type":36},{"date":601,"type":4},"2010-07",{"date":603,"type":21},"2027-07",{"name":42,"class":43},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":614,"conditions":615,"keywords":619,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":630},"100619184","sars-cov-2-mrna-vaccination-in-patients-with-hepatocellular-carcinoma-treated-with-immune-checkpoint-inhibitors-100619184","NCT07341321","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria","CoVaCheck","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Radiologically or histologically confirmed hepatocellular carcinoma\n* Treatment with immune checkpoint inhibitor-based therapy (mono- or combination therapy; e.g., atezolizumab\u002Fbevacizumab, durvalumab\u002Ftremelimumab, nivolumab, pembrolizumab)\n* Complete electronic medical records available\n* At least one imaging-based response assessment using mRECIST\n\nExclusion Criteria:\n\n* Missing key clinical data required for main analyses (e.g. survival status, date of progression, Child-Pugh class, BCLC stage)",{"count":528,"type":21},"A multicenter retrospective cohort analysis in Austria\n\nPrimary Objective:\n\nTo assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma).\n\nSecondary Objectives:\n\nEvaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).",[616,617,618],"mRNA Vaccination","Hepatocellular Carcinoma","Checkpoint Inhibitor",[620,621,180,622],"hepatocellular carcinoma","mRNA vaccination","immune checkpoint inhibitor","2026-01-07",{"date":560,"type":36},{"date":626,"type":21},"2026-01",{"date":628,"type":21},"2026-12",{"name":42,"class":43},5,{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":44},"100584575","implementation-of-an-empiric-transfusion-bundle-for-out-of-hospital-patients-with-haemorrhagic-shock-100584575","NCT06891131","Implementation of an Empiric Transfusion Bundle for Out of Hospital Patients With Haemorrhagic Shock","Implementation of an Empiric Transfusion Bundle for Out of Hospital Patients With Haemorrhagic Shock: a Prospective Observational Study C-TOP - Coagulation Therapy for Out-of-Hospital Patients","C-TOP","Inclusion Criteria:\n\n* aged, or believed to be aged\n* 18 years or above\n* confirmed or suspected life-threatening bleeding from trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss)\n* need for volume replacement therapy.\n\nExclusion Criteria:\n\n* patient with known recent history of thromboembolic events within the last 6 months\n* known or suspected pregnancy at presentation\n* patient with known refusal of a participation in this clinical trial.",{"count":640,"type":21},10,"The investigators will evaluate the implementation of a treatment bundle (Fibrinogen, Plasma and Tranexamic Acid)",[643,91],"Haemorrhagic Shock",[645,646,647,648],"Trauma","coagulopathy","haemmorhage","transfusion","2025-12-09",{"date":651,"type":36},"2025-12-17",{"date":653,"type":36},"2025-06-01",{"date":655,"type":21},"2027-06-01",{"name":42,"class":43},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":116,"phases":667,"briefSummary":668,"conditions":669,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":44},"100394888","periinterventional-coagulation-management-of-patients-undergoing-a-tips-100394888","NCT04421924","Periinterventional Coagulation Management of Patients Undergoing a TIPS","Optimizing Periinterventional Coagulation Management of Patients Undergoing a Transjugular Intrahepatic Portosystemic Shunt Implantation: A Prospective Randomized Cohort Study","TIPSprosp","inclusion criteria\n\n* Liver cirrhosis\n* \\>18 years\n* Indication for TIPS implantation\n* Ability to sign informed consent exclusion criteria\n* Contraindications against TIPS implantation\n* Hepatocellular carcinoma BCLC D\n* Ongoing bleeding\n* pre-existing anticoagulant therapy at time of inclusion\n* administration of blood products within 1 week prior to the enrolment\n* Other malignancies that lead to an impaired 90-day survival\n* Inherit blood clotting disorders\n* Hepatic encephalopathy grade 3 or 4\n* any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol",{"count":666,"type":21},39,[118],"Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective",[670],"Liver Cirrhosis","2025-12-02",{"date":649,"type":36},{"date":674,"type":36},"2020-05-27",{"date":676,"type":21},"2027-05",{"name":42,"class":43},""]